bluuebunny/crossref_metadata_2025_split huggingface dataset:
Patient characteristics, treatment patterns and outcomes for patients with renal cell carcinoma in England: A retrospective cohort study using data from the National Cancer Registry and treatment and hospital data.
Authors: Das Prantik , Clark Andrew , Nordstrom Beth , Booth Alison , Dhokia Poonam , Carroll Robert , Vaz Luis 
Published: March 2023

639 Background: Renal cell carcinoma (RCC) is the seventh most common cancer in the UK. It is necessary to examine recent treatment trends and outcomes in England to understand the evolving landscape. The primary aim was to describe the demographic and clinical characteristics of patients with RCC, and assess their overall survival (OS) and treatment duration, overall and by subgroups of interest. Secondly, we aimed to understand use of systemic therapies over time. Methods: This was a retrospective cohort study of patients diagnosed with RCC during 2014-2018 using national registry, treatment and hospital data in England. Descriptive statistics were explored with Chi-squared, Fishers exact and Wilcoxon rank sum tests. OS and treatment duration were analysed using Cox regression models to provide hazard ratios (HR) with 95% CI. Kaplan Meier curves were used to compare the proportion of patients alive or on treatment. Results: The cohort included 32,577 individuals; median age at diagnosis 67 years; 36.6% of patients were female; 81.4% exhibited clear cell histology. RCC diagnosed at stage I-III appeared to increase from 61% in 2015 to 68% in 2018. A total of 5,657 patients received at least 1 line of systemic treatment, decreasing to 2,606 and 989 patients for 2 and 3 treatment lines; at 3 months, treatment persisted for 59.9%, 19.0% and 20.5% respectively. In the cohort, 25,566 (78.5%, 95% CI: 78.0–78.9) were alive 1 year from the date of diagnosis and 21,856, (67%, 95% CI: 66.6–67.6) were alive at 3 years. In the subgroup with metastatic disease, 6,786 (37.1%, 95% CI: 35.9–38.2) were alive at 1 year which decreased to 18.0% (95% CI: 17.06–18.92) at 3 years. Among patients with metastatic disease at initial diagnosis, OS was reduced in those with non-clear cell compared to clear cell RCC (HR: 1.19 [95% CI 1.07-1.33]), and those without nephrectomy had a lower probability of survival compared with those who did have a nephrectomy (HR: 2.54, 95% CI: 2.34–2.75). Conclusions: This study presents the most recent and extensive RCC data from England, examining treatment duration, overall survival and patient demographics at presentation, by histology, metastatic status and line of therapy subgroups. These findings could facilitate exploration of potential unmet needs, inequities of treatment or risk factors for patients.
Renal function and survival following treatment for cT1N0 renal cell carcinoma in a veteran population.
Authors: Kumar Abhishek , Salama Joseph Kamel , Boyer Matthew J 
Published: March 2023

642 Background: Radical nephrectomy (RN), nephron sparing surgery (NSS) and thermal ablation (TA) are associated with similar oncologic control for early-stage renal cell carcinoma (RCC). However, the potential protective role of nephron sparing treatments on renal function and its impact on non-cancer related mortality remains undetermined. Methods: We employed the national Veterans Affairs Corporate Data Warehouse (CDW) to identify patients diagnosed with cT1N0 RCC between 2000-2018. Laboratory and diagnosis data were used to calculate creatinine clearance and Charlson comorbidity score. Chronic kidney disease (CKD) was defined as creatinine clearance < 60 milliliters per minute. Kaplan-Meier analysis and multivariable Cox regression analysis were used to evaluate overall survival. Results: Overall, there were 8279 Veterans with cT1N0M0 renal cell carcinoma diagnosed between 2000-2018 who received either RN (2946, 36%), NSS (4846, 59%) or TA (487, 6%). Median follow up time was 8 years (90% CI 2-15 years). Patients receiving RN were older than those receiving NSS (median age 64.0 vs 62.6 years, p<0.01) but younger than those receiving TA (median age 67.9 years, p<0.01). Patients receiving RN and TA had more comorbidities than patients receiving NSS (mean Charlson scores 0.76 vs. 1.00 vs. 0.66, p<0.01. More patients among the RN group had CKD before RCC diagnosis than the NSS and TA groups (10% vs. 6% vs. 7%, p<0.01). Among the subset of patients without CKD before treatment, 17% of RN, 8% of NSS, and 11% of TA developed CKD at least 1 year after treatment, (p <0.01). Median OS was 11.5 years with RN, 14.2 years with NSS, and 10.3 years with TA. On multivariable analysis considering age, comorbidities, CKD, race, and year of treatment, compared to RN, NSS was associated with better OS (HR 0.75, p<0.01) with a trend to improved survival with TA (HR 0.88, p=0.08). Conclusions: NSS or TA are associated with less post-operative renal dysfunction than RN in patients treated for cT1N0 RCC in the VAHCS. NSS is associated with improved OS compared to RN. Further studies are warranted to assess the impact of renal dysfunction in this population in relation to oncologic and survival outcomes.
2022 Global patient survey: Reported experience of diagnosis, management, and burden of renal cell carcinomas.
Authors: Giles Rachel H. , Maskens Deborah , Marconi Lorenzo , Martinez Robin , Kastrati Karin , Castro Carlos , Julian Mauro Juan Carlos , Bick Robert , Hickey Margie , Heng Daniel Yick Chin , Larkin James , Bex Axel , Jonasch Eric , Maclennan Sara Jane , Jewett Michael A.S. 
Published: March 2023

653 Background: Kidney cancer (renal cell carcinoma, RCC) has shown a sustained increase in its global prevalence thereby presenting increasing burden to health systems, and most of all, to individual patients and their families. Little is known about the variations in the patient experience and best practices among countries. Although individual national surveys have been held, no conclusions could be drawn about country-level variation in patient experience or best practice. Here, we report on the 3rd biennial Global Patient Survey on the diagnosis, management, and burden of Renal Cell Carcinomas conducted by the International Kidney Coalition (IKCC) and involving its Affiliate Organisations worldwide in 15 languages. The aim of the survey was to improve collective understanding and to contribute toward the reduction of the burden of kidney cancer around the world. Methods: A 35-question survey on the diagnosis, management, and burden of RCC was designed by a multi-country steering committee of patient leaders to identify geographic variations in 6 key dimensions: patient education, experience and awareness, access to care and clinical trials, best practices, quality of life, and unmet psychosocial needs. EAU, ESMO, ASCO and NCCN Guidelines committees provided topics of interest to support evidence-based medicine (eg patient perspective on active surveillance, biopsies, etc) . The survey was distributed to patients with kidney cancer and their caregivers in 15 languages, through social media and IKCC’s 49 Affiliate Organizations and/or allied organizations who are not formal affiliates. It was completed online or in paper form between 26 September 2022 and 31 October 2022. At the time of this abstract submission, the survey was still open for completion. Results: We will present the top-line results of the 2022 survey for the very first time. Survey results will be analyzed using cross-tabulations by an independent third-party organization, and multi-variate analysis of predetermined variable will be performed. The full global report will be presented, as well as individual country reports where at least 100 responses were received. Conclusions: The IKCC and its global affiliates will be using the results to ensure that patients’ voices are heard. Actionable points will suggest future projects. Furthermore, individual countries can use their reports to advance their understanding of patient experiences and to drive improvements in care provision locally.
Is pathological upstaging to T3a renal cell carcinoma associated with a similar prognosis to non-upstaged pathologic T3a disease? A multicenter analysis.
Authors: Nasseri Ryan , Hakimi Kevin , Afari Jonathan , Saidian Ava , Autorino Ricardo , Lane Brian R. , Marchioni Michele , Patil Dattatraya H , Sundaram Chandru , Tanaka Hajime , Porpiglia Francesco , Noyes Sabrina L. , Porter James R , Master Viraj A. , Minervini Andrea , Capitanio Umberto , Montorsi Francesco , Derweesh Ithaar H 
Published: March 2023

656 Background: Pathological upstaging to T3a disease may occur following radical (RN) or partial nephrectomy (PN) for patients with T1/T2 renal cell carcinoma (RCC). While a number of studies have demonstrated increased risk of T1/T2 upstaging to pT3a compared to initial staging, a comparison of pathologically upstaged T3a RCC and T3a RCC which was not upstaged has not been performed. We sought to compare survival outcomes and predictors of outcomes in patients who underwent surgical therapy for upstaged T3a RCC versus non-upstaged pT3a RCC. Methods: We conducted a retrospective analysis of a multi-institutional dataset of patients who underwent radical (RN) or partial nephrectomy (PN) with final pathologic stage of pT3a. Patients were classified as being upstaged (US) from cT1 or cT2 or non-upstaged (NUS) with cT3a disease. Primary outcome was Overall Survival (OS)/all-cause mortality (ACM). Secondary outcomes were Cancer-Specific Survival (CSS)/Cancer-Specific Mortality (CSM), and Recurrence-Free survival (PFS)/Recurrence. Multivariable Cox regression analysis (MVA) were conducted for predictors of mortality outcomes and Kaplan Meier Analyses (KMA) were conducted to elucidate survival outcomes comparing US and NUS groups. Results: We analyzed 879 patients [US 691 (cT1 389/cT2 302); NUS 188; median follow-up 48 months). NUS had significantly greater tumor size (9.3 vs. US 7.3 cm, p<0.001), but no difference in positive surgical margins (6.9% vs. 3.9%, p=0.16). MVA for ACM revealed RN (HR 4.35, p<0.001), clear-cell RCC (HR 2.38, p<0.001), and positive surgical margin (HR 2.24, p=0.023) were independently associated, while upstaging status was not (p=0.78). MVA for CSM demonstrated age (HR 1.04, p=0.024) and positive margin (HR 5.28, p=0.029) were independently associated, while upstaging status was not (p=0.14). MVA for recurrence revealed positive margin (HR 6.7, p=0.003) and NUS (HR 3.85, p=0.001) to be associated with increased risk. KMA Comparing NUS and US groups, revealed no difference in 5-year OS (57% NUS vs. US 56%, p=0.38), and worsened 5-year CSS (NUS 66% vs. US 75%, p=0.04) and 5-year RFS (NUS 60% vs. US 84%, p<0.001). Conclusions: Pathologic upstaging to T3a RCC was associated with a lower risk of recurrence compared to non-pathologically upstaged T3a RCC; nonetheless in our analysis upstaging status was not independently associated with increased risk of cancer-specific or overall mortality in T3a RCC. Our findings also highlight the importance of complete surgical resection in the setting of T3a disease and should prompt consideration of intensified follow up, aggressive re-salvage resection and use of adjuvant therapy.
Association of inflammation and depression in renal cell carcinoma.
Authors: Schmeusser Benjamin , Ali Adil , Patil Dattatraya H , Midenberg Eric , Petrinec Benjamin , Bilen Mehmet Asim , Ogan Kenneth , Master Viraj A. 
Published: March 2023

658 Background: Patients with cancer experience depression at higher rates, which is associated with worse outcomes and quality of life. In renal cell carcinoma (RCC) specifically, depression is particularly prevalent. Aside from the emotional distress of a cancer diagnosis, a biologic basis for cancer associated depression is inflammation, which is highly associated with RCC as well as worse outcomes. Here, we aim to assess the association between inflammation and major depression, measured by a score of 10+ on the Patient Health Questionnaire (PHQ-8), in patients undergoing nephrectomy for nonmetastatic RCC. Methods: A retrospective review of prospectively administered PHQ-8 surveys in patients that underwent nephrectomy for nonmetastatic RCC was conducted. Patients with available preoperative PHQ-8 within 180 days before surgery were included. Association of major depression on PHQ-8 with patient/tumor characteristics were determined by Generalized chi-square test or Fisher’s exact test for categorical variables and Wilcoxon rank-sum test for continuous variables. Multivariable logistic regression was used to determine variables significantly associated with major depression on PHQ-8, including pre-operative C-Reactive Protein (CRP) independently and combined with American Joint Committee on Cancer (AJCC) staging for RCC. Results: 224 patients were analyzed, with 67% being male. Median age and BMI was 64 and 29.0, respectively. 65.2% of patients were white, and 28.6% were black. Histologically, most patients had clear cell RCC (67.4%). AJCC staging was 52.2% stage I, 5.36% stage II, and 42.41% stage III. 30.4% had an elevated CRP (>10mg/L). Median PHQ-8 score was 4, with 42 (18.8%) of patients screening positive for major depression on PHQ-8 (10+). Multivariable regression models showed elevated CRP alone (OR 2.74, 95% CI 1.02-7.40, p=0.047) and in-combination with AJCC stage I-II (OR=8.13, 95% CI 1.99-33.27, p=0.004) and III (OR=4.82, CI 1.11-20.88, p=0.035) as a predictor of major depression on PHQ-8. Conclusions: In this study of patients with nonmetastatic RCC, elevated CRP (>10mg/L) was an independent predictor of major depression on PHQ-8. [Table: see text]
Impact of age on functional decline following radical nephrectomy: Analysis of the International Marker Consortium for Renal Cancer (INMARC).
Authors: Nguyen Mimi , Walia Arman , Saidian Ava , Wang Luke , Hakimi Kevin , Meagher Margaret , Cerrato Clara , Shah Aastha , Liu Franklin , Dhanji Sohail , Patil Dattatraya H , Fujii Yasuhisa , Derweesh Ithaar H 
Published: March 2023

664 Background: Radical nephrectomy (RN) is a mainstay of management of localized renal cancer >4 cm. RN is associated with renal functional decline, however impact of age on functional decline is unclear. We investigated impact of age on post RN function, focusing on decline to moderate and severe chronic kidney disease (CKD). Methods: This was a retrospective analysis of patients who underwent RN. Patients were stratified by age (<50, 50-70 and >70 years). Primary outcome was development of denovo CKD-S 3b [estimated glomerular filtration rate (eGFR) <45 mL/min/1.73m2)]. Secondary outcomes included denovo CKD-S 3a (eGFR<60) and denovo CKD-S 4 (eGFR<30). Multivariable logistic regression analysis (MVA) was utilized to identify risk factors for renal functional decline. Linear regression was utilized to identify risk factors for increasing DeGFR. Kaplan-Meier analysis (KMA) was utilized to evaluate functional outcomes for different age groups Results: We analyzed 2436 patients (<50 years, n=513; 50-70 years, n=1344; >70, n=579; median follow-up 31.9 months). On MVA, increasing age was an independent risk factor for CKD-S 3a (HR=3.4-9.4, p<0.001), CKD-S 3b (HR=3.4-7.7, p<0.001), and denovo CKD-S 4 (HR=1.96, p=0.027). On linear-regression analysis, increasing age was significantly correlated with increased delta eGFR (β=-0.212, p<0.001). KMA Comparing <50, 50-70 and >70 demonstrated age-associated declines in 5-year freedom from denovo CKD-S 3a (73.9%; 50-70 53.7%; and >70 37.06%, respectively, p<0.001), denovo CKD-S 3b (92.7%; 71.8%; and 55.5%, p<0.001) and denovo CKD-S 4 (93.7%; 89.8%; and >70 81.2%, p<0.001). Conclusions: Increasing age is a risk factor for progressive and clinically significant renal functional decline after RN. Prioritization for nephron-sparing management may be considered when indicated and oncologically safe and feasible in elderly patients to reduce potential risk of sequelae of functional decline. [Table: see text]
Overall survival, efficacy, and safety outcomes beyond front-line modern therapies in metastatic clear-cell renal cell carcinoma.
Authors: Kreutzfeldt Jordyn , Obeng-Kusi Mavis , Estrada-Mendizabal Ricardo J. , Choi Briana M , Abraham Ivo , Recio-Boiles Alejandro 
Published: March 2023

667 Background: Due to the ever-changing front-line landscape therapeutic options for m-ccRCC, the second-line (2L) treatment decision remains challenging due to limited information comparing each of the options. We present a survival, efficacy, and safety comparison of the 2L treatment regimens based on the most recent drug approvals for m-ccRCC. Methods: Inclusion criteria for our NMA included phase II/III RTCs that evaluated 2L and beyond for metastatic ccRCC. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and severe adverse events (SAE) hazard ratios (HRs), odds ratios (OR), and 95% confidence intervals (CI) of the treatment differences were abstracted. The p-scores were used to rank treatments. Data were analyzed in a fixed effects model using the netmeta package in R v.1.5-0. Results: Nine studies with 10 therapies included demonstrated some level of efficacy over placebo (Table). Pairwise comparisons using the NMA matrix revealed no differential OS benefit between axitinib (A), cabozantinib (C), lenvatinib+everolimus (LE), and nivolumab (N). Other regimens had no OS benefit when compared to placebo. Table was ordered based on p-score ranking the certainty that one treatment is better than another averaged over all competing treatments for OS. Placebo represents the reference of 1. Conclusions: LE had the lowest safety profile, although did prove to have the best OS and efficacy based on PFS/ORR. C and N, both had significant improvement in OS and efficacy over placebo with lower rates of SAEs compared to LE. Therefore, while further direct comparison studies are warranted to inform clinical practice, for now, we rely on the limitations inherent in indirect treatment comparisons of a NMA. [Table: see text]
Phase II trial of intermittent therapy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with front-line ipilimumab and nivolumab (Ipi/Nivo).
Authors: George Laeth , Wei Wei , Diaz-Montero C. Marcela , Martin Allison , Vyas Neil , Basu Arnab , Beckermann Katy , Nizam Amanda , Wee Christopher Eing , Gilligan Timothy D. , Gupta Shilpa , Rini Brian I. , Ornstein Moshe Chaim 
Published: March 2023

672 Background: The combination of ipilimumab and nivolumab (Ipi/Nivo) is approved for patients (pts) with treatment-naïve, intermediate- and poor-risk metastatic renal cell carcinoma (mRCC), but duration of therapy and safety/efficacy of re-induction at progression is unknown. A phase II trial of intermittent Ipi/Nivo with re-induction at progression was conducted (NCT03126331). Methods: Patients with treatment-naïve mRCC were treated with induction Ipi/Nivo followed by up to 24 weeks (+/- 8 weeks) of maintenance Nivo. Pts who achieved a complete response (CR) or partial response (PR) were eligible for inclusion and entered a treatment-free observation period. Pts were restaged every 12 weeks. Pts with no disease progression (PD) remained off therapy. Upon PD, pts were re-challenged with 2 doses of Ipi/Nivo every 3 weeks, with 1 or 2 more doses at physician discretion. The study objectives were to estimate success rate of observation in pts who achieve a CR/PR (defined by 50% of CR/PR pts sustaining a treatment-free interval of at least 9 months), and to assess toxicity in pts undergoing re-induction. The study was closed early given poor accrual in the rapidly changing mRCC treatment landscape. Results: Nine pts were included; 89% male, median age 57, 78% prior nephrectomy, 67% clear-cell histology, all had KPS ≥ 80%, and 78% were intermediate-risk by IMDC criteria. All pts had 4 doses of induction Ipi/Nivo. Response to Ipi/Nivo and Nivo maintenance prior to enrollment was 33% CR and 67% PR. Most (78%) pts patients have remained off therapy, with a median treatment-free interval (TFI) of 34.3 months (range, 8.7-41.8). The success rate of 0.78 (95% CI: 0.40-0.97) exceeded the pre-specified threshold of 50%. Two pts had PD off therapy (3 and 8 months after therapy cessation; both with best initial response of PR). Both received 2 cycles of re-induction Ipi/Nivo. No grade 3 or greater toxicities occurred with re-induction, but both pts developed PD at their first scans after re-induction. Conclusions: This pilot prospective study demonstrates that patients with a radiographic response to Ipi/Nivo can have prolonged treatment-free intervals. Further studies of de-escalation strategies are warranted. Correlative investigations for this trial are ongoing. Clinical trial information: NCT03126331 .
Survival outcomes of metastasis-directed therapy for solitary sites of metastatic clear cell renal cell carcinoma.
Authors: Lewis Akeem Ronell , Lohse Christine M. , Lyon Timothy D. , Cheville John , Leibovich Bradley C. , Sharma Vidit , Costello Brian Addis 
Published: March 2023

674 Background: Metastasis directed therapy (MDT) is associated with improved cancer-specific survival and delay in use of systemic therapy for metastatic clear cell RCC (mccRCC). Although the benefits of MDT may differ based on organ site of metastasis due to differences in disease biology, survival based on site of metastasis remain underexplored. We aim to evaluate survival outcomes of patients who underwent MDT for solitary sites of mccRCC. Methods: The Mayo Clinic Nephrectomy Registry was queried to identify adults undergoing radical or partial nephrectomy for unilateral, sporadic ccRCC from 2000 to 2019 with a single site of metastasis treated with MDT including complete metastasectomy or radiation, in lieu of systemic therapy. Overall and cancer-specific survival were estimated using the Kaplan-Meier method, with the duration of follow-up calculated from the date of metastasis to the date of death or last follow-up. Associations with time to death from RCC were evaluated using Cox proportional hazards regression models and summarized with hazard ratios and 95% confidence intervals (CIs). Results: In this cohort of 207 mccRCC patients, 152 underwent complete metastasectomy and 55 underwent radiation. 133 died at a median of 2.7 years (IQR 1.2-4.7) following metastasis, including 105 who died from RCC at a median of 2.2 years (IQR 1.0-3.9). The median duration of follow-up for the 74 patients who were still alive at last follow-up was 8.1 years (IQR 3.7-12.1). Overall survival rates (95% CI) at 2, 4, 6, 8, and 10 years following metastasis were 73% (69-79), 54% (48-62), 45% (38-52), 37% (30-44), and 32% (26-40), respectively; cancer-specific survival rates were 75% (69-81), 56% (50-64), 47% (41-55), 44% (37-52), and 42% (35-50), respectively. Age, poor performance status, presence of synchronous metastasis and asynchronous metastasis <1 year from nephrectomy, tumor size, and bone metastasis were associated with death from RCC (table). Conclusions: These findings provide useful survival benchmarks to patients who are considering MDT as a therapeutic option. In addition, synchronous and asynchronous metastasis <1 year from nephrectomy, poor performance status, and bone metastasis are significantly associated with worse survival from mccRCC. [Table: see text]